Merger to create publicly-listed, commercial-stage leader in hybrid intravascular imaging
News | Cardiovascular Business
Titan Announces Merger Agreement with Conavi

March 19, 2024 — Titan Medical Inc. announced that it has entered into a definitive amalgamation agreement (the ...

Home March 19, 2024
Home
A clinical trial at Cedars-Sinai is testing the safety and efficacy of a device aimed at managing treatment-resistant hypertension. Photo by Getty.
News | Hypertension
Cedars-Sinai Experts Studying Device for Controlling Treatment-Resistant Hypertension

March 18, 2024 — The Smidt Heart Institute at Cedars-Sinai recently became one of four institutions in the U.S. and the ...

Home March 18, 2024
Home
The first mitral valve replacement using the made in India SSi Mantra Surgical Robotic System was successfully performed at the Narayana Institute of Cardiac Sciences in Bengaluru, India
News | Robotic Systems
SS Innovations’ SSi Mantra Surgical Robotic System used to perform Mitral Valve Replacement

March 18, 2024 — SS Innovations International, Inc., a developer of innovative surgical robotic technologies dedicated ...

Home March 18, 2024
Home
Visual Thrombus Assessment as presented by Dr. William Gray at the Cardiovascular Research Technologies (CRT) 2024 conference.
News | Left Atrial Appendage (LAA) Occluders
Conformal Medical's CLAAS System Demonstrates Low Thrombogenicity Compared to Commercially Available LAAO Devices

March 18, 2024 — Conformal Medical, Inc. announced that the CLAAS System was featured in a podium presentation at the ...

Home March 18, 2024
Home
Biotronik Launches Its Complete Conduction System Pacing (CSP) Solution Consisting of the World’s First Approved CSP System Alongside Comprehensive Training and Expert Support
News | Pacemakers
Biotronik Introduces World’s First and Only System CE Approved for Left Bundle Branch Area Pacing (LBBAP)

March 15, 2024 — Following the recent CE approval of the Solia S lead1 for LBBAP, BIOTRONIK proudly announces the world ...

Home March 15, 2024
Home
Partnership targets heart failure, the leading cause of death and a condition with limited treatment options
News | Heart Failure
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership

March 15, 2024 — BioCardia, Inc. , a biotechnology company focused on advancing late-stage cell therapy interventions ...

Home March 15, 2024
Home
Partnership targets heart failure, the leading cause of death and a condition with limited treatment options
News | Cardiovascular Business
Gilbert H. L. Tang Appointed Editor-in-Chief of JACC: Case Reports

March 15, 2024 —Renowned cardiovascular surgeon Gilbert H. L. Tang, MD, has been named Editor-in-Chief of JACC: Case ...

Home March 15, 2024
Home
Biotronik Launches Its Complete Conduction System Pacing (CSP) Solution Consisting of the World’s First Approved CSP System Alongside Comprehensive Training and Expert Support
News | Pacemakers
Biotronik Introduces World’s First and Only System CE Approved for Left Bundle Branch Area Pacing (LBBAP)

March 15, 2024 — Following the recent CE approval of the Solia S lead1 for LBBAP, Biotronik announces the world’s first ...

Home March 15, 2024
Home
Partnership targets heart failure, the leading cause of death and a condition with limited treatment options
News | Heart Failure
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership

March 15, 2024 — BioCardia, Inc., a biotechnology company focused on advancing late-stage cell therapy interventions for ...

Home March 15, 2024
Home
Partnership targets heart failure, the leading cause of death and a condition with limited treatment options
News | Cardiovascular Business
Gilbert H. L. Tang Appointed Editor-in-Chief of JACC: Case Reports

March 15, 2024 —Renowned cardiovascular surgeon Gilbert H. L. Tang, MD, has been named Editor-in-Chief of JACC: Case ...

Home March 15, 2024
Home
In a new letter sent to federal officials on March 12, the American Medical Association (AMA) has presented six relief proposals to support physicians impacted by Change Healthcare hack, and praised the creation of the Change Healthcare/Optum Payment Disruption (CHOPD) Accelerated Payments.
News | Cybersecurity
AMA Presents Relief Proposals to Federal Officials to Support Physicians Impacted by Change Healthcare Hack

March 14, 2024 — The American Medical Association (AMA) has issued a new letter to federal officials in which it praised ...

Home March 14, 2024
Home
First-of-its-kind trial in US shows drug-coated balloons are a superior treatment option for patients undergoing coronary angioplasty
News | Cardiovascular Clinical Studies
BIDMC-led Trial Leads to FDA approval of Coronary Drug-coated Balloons

March 13, 2024 — In the largest randomized clinical trial and first of its kind to date in the United States, a team led ...

Home March 13, 2024
Home
BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced Centers for Medicare & Medicaid Services (CMS) approval for reimbursement coverage of the confirmatory Phase III clinical trial of CardiAMP autologous cell therapy for the treatment of patients with ischemic heart failure.
News | Heart Failure
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

March 13, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home March 13, 2024
Home
New Jersey-based Atlantic Health System’s Morristown Medical Center and New York-based NYU Langone Health, both nationally recognized cardiovascular programs, have announced that they are expanding their partnership to provide patients improved access to adult congenital heart disease services and the specialist directed care. Shown here, Trish O’Keefe, Senior Vice President, and President of Morristown Medical Center.
News | Cardiovascular Business
Atlantic Health System’s Morristown Medical Center and NYU Langone Health Expand Partnership to Include Adult Congenital Heart Disease

March 13, 2024 — Two nationally recognized cardiovascular programs, New Jersey-based Atlantic Health System’s Morristown ...

Home March 13, 2024
Home
Silence Therapeutics has announces positive topline 36-week data from its ongoing Phase 2 Study of Zerlasiran in patients with high Lipoprotein(a), reporting that the study met the primary endpoint and demonstrated highly significant reductions in Lp(a) to week 36.
News | Cardiovascular Clinical Studies
Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lp(a) Announced by Silence Therapeutics

March 13, 2024 — Silence Therapeutics has announced positive topline 36-week data from the ongoing ALPACAR-360 phase 2 ...

Home March 13, 2024
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now